Bcl-2 antisense (oblimersen sodium) plus dacarbazine in patients with advanced melanoma: the Oblimersen Melanoma Study Group.

@article{Bedikian2006Bcl2A,
  title={Bcl-2 antisense (oblimersen sodium) plus dacarbazine in patients with advanced melanoma: the Oblimersen Melanoma Study Group.},
  author={Agop Y. Bedikian and Michael Millward and Hubert Pehamberger and Robert M Conry and Martin Gore and Uwe Trefzer and Anna C Pavlick and Ronald Deconti and Evan M. Hersh and Peter Hersey and John Munn Kirkwood and Frank G. Haluska},
  journal={Journal of clinical oncology : official journal of the American Society of Clinical Oncology},
  year={2006},
  volume={24 29},
  pages={4738-45}
}
PURPOSE Chemotherapy resistance in melanoma has been linked to antiapoptotic effects mediated by Bcl-2 protein. We evaluated whether targeting Bcl-2 using an antisense oligonucleotide (oblimersen sodium) could improve the efficacy of systemic chemotherapy in patients with advanced melanoma. PATIENTS AND METHODS We randomly assigned chemotherapy-naïve patients with advanced melanoma to treatment with dacarbazine (1,000 mg/m2) alone or preceded by a 5-day continuous intravenous infusion of… CONTINUE READING